STOCK TITAN

Syneos Health Schedules Third Quarter 2020 Earnings Call for Thursday, October 29, 2020

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

MORRISVILLE, N.C., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2020 financial results on Thursday, October 29, 2020, prior to its earnings call at 8:00 a.m. ET.

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 4294655.

A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on October 29. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 4294655.

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Investor Relations Contact: Press/Media Contact:
Ronnie SpeightDanielle DeForge
Senior Vice President, Investor RelationsExecutive Director, External Communications
+1 919 745 2745+1 781 425 2624
investor.relations@syneoshealth.comdanielle.deforge@syneoshealth.com 
Syneos Health, Inc.

NASDAQ:SYNH

SYNH Rankings

SYNH Latest News

SYNH Stock Data

4.46B
103.27M
0.49%
94.75%
6.52%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Morrisville

About SYNH

inc research/inventiv health has become syneos health, the only fully integrated end-to-end clinical and commercial solution organization. we are purpose-built for biopharmaceutical acceleration, creating better, smarter, faster ways to help clients navigate an increasingly complex marketplace. our new business addresses today’s market realities through clinical and commercial sharing expertise and data and insights to meet the needs of emerging and large global biopharmaceutical companies.